Tomasz Sablinski is a co-founder and CEO of Transparency Life Sciences, world’s first digital drug development company. He is passionate about changing clinical research by converging modern information technology with drug development “know-how” to increase the speed and quality of advancement of pharmaceuticals and biologics pipelines. His 35 years of experience in healthcare include 20 years of clinical development at Novartis, Parexel, consulting for biotechnology companies and managing a development portfolio at Auven Therapeutics. In the 1990s Dr. Sablinski was a member of teams at Harvard Medical School (Brigham and Women’s and Massachusetts General Hospitals) conducting pioneering work in developing biologic immunosuppressive regimens, induction of transplantation tolerance and xenotransplantation. He also practiced as a surgeon specializing in renal transplantation and general surgery in his native Poland and in Boston. Dr. Sablinski received his MD and PhD degrees from the Medical University of Warsaw in Poland.